Having trouble finding Myfortic at your pharmacy? Learn why this transplant medication is hard to find in 2026 and what you can do to get it filled.
You've been taking Myfortic (Mycophenolic Acid) faithfully since your kidney transplant. It's one of the medications keeping your body from rejecting your new organ. So when your pharmacy tells you they don't have it in stock — or worse, they're not sure when it'll be back — it can feel like the ground just dropped out from under you.
You're not imagining things. Myfortic and its generic versions have been increasingly difficult to find at pharmacies across the country. In this article, we'll break down exactly why Myfortic is so hard to find in 2026, and more importantly, what you can do about it.
Myfortic is the brand name for Mycophenolic Acid, a delayed-release tablet made by Novartis. It belongs to a class of drugs called selective immunosuppressants. Doctors prescribe it to prevent organ rejection in people who have received a kidney transplant.
Myfortic works by blocking an enzyme called inosine monophosphate dehydrogenase (IMPDH), which your immune system's T-cells and B-cells need to multiply. By slowing down these cells, Myfortic helps stop your body from attacking the transplanted kidney.
It comes in two tablet strengths — 180 mg and 360 mg — and the typical adult dose is 720 mg taken twice a day. The tablets have a special enteric coating that protects your stomach by releasing the medication in your small intestine instead.
Myfortic is usually taken alongside Cyclosporine and a corticosteroid as part of a transplant maintenance regimen. For more details on what this drug does, check out our guide: What Is Myfortic? Uses, Dosage, and What You Need to Know.
There isn't one single reason Myfortic is tough to locate at pharmacies. It's a combination of factors hitting at the same time.
While brand-name Myfortic from Novartis has generally stayed available, the generic versions of Mycophenolic Acid delayed-release tablets have faced manufacturing disruptions. When one or more generic makers run into production issues — equipment problems, raw material shortages, or quality control delays — the entire supply chain feels it. Because most pharmacies stock the generic version (which costs significantly less), a generic shortage can make it feel like Myfortic has disappeared entirely.
Unlike common drugs like blood pressure pills, Myfortic is classified as a specialty medication. That means pharmacies don't keep large quantities on their shelves. Many retail chain pharmacies may only stock it when a patient has an active prescription, and even then, they may order it on a just-in-time basis. If their distributor is out, you're out of luck.
Myfortic is used almost exclusively by kidney transplant recipients and some patients with autoimmune conditions like lupus. That's a relatively small group compared to, say, people taking Metformin for diabetes. Pharmacies stock medications based on demand, and a drug with a smaller patient base simply gets fewer slots on the shelf.
Even when a pharmacy has Myfortic in stock, insurance red tape can slow things down. Many insurance plans require prior authorization before they'll cover Myfortic, especially the brand-name version. Some plans use step therapy, meaning they want you to try Mycophenolate Mofetil (CellCept) first before approving Myfortic. These delays can leave patients scrambling to find their medication before they run out.
Running low on an immunosuppressant is serious. Missing even a few doses can increase your risk of organ rejection. Here are steps you can take right now:
Instead of calling pharmacy after pharmacy, use Medfinder to search for Myfortic availability at pharmacies near you. Medfinder checks stock in real time, saving you hours of phone calls and drive-arounds.
Big chain pharmacies aren't your only option. Independent pharmacies often have more flexibility with their ordering and may carry specialty medications that chains don't prioritize. Specialty pharmacies that focus on transplant medications are another excellent resource — they're more likely to have Myfortic on hand.
Your transplant coordinator or nephrologist deals with medication access issues regularly. They may know which local pharmacies reliably stock Myfortic, or they might be able to provide bridge supplies from the clinic's own pharmacy while you locate a fill.
If the generic Mycophenolic Acid is what's out of stock, ask your doctor about writing a prescription specifically for brand-name Myfortic. Novartis has generally maintained a steady supply. Yes, it costs more, but Novartis offers savings through their SaveOnMyPrescription.com program that can bring down the price significantly.
The cost of Myfortic without insurance can run $750 to $900 per month. But with GoodRx coupons, generic Mycophenolic Acid can drop to as low as $43 per month. For more tips on cutting costs, read our article on How to Save Money on Myfortic in 2026.
If you're down to your last few doses and can't find a pharmacy with Myfortic in stock, take these steps immediately:
For a deeper look at alternatives, see our guide: Alternatives to Myfortic If You Can't Fill Your Prescription.
Finding Myfortic shouldn't be this hard, but the reality of specialty drug supply chains, generic manufacturer disruptions, and insurance hurdles means that transplant patients sometimes face gaps in access. The good news is that tools like Medfinder exist to help you track down your medication faster, and there are real steps you can take to protect yourself from running out.
Stay proactive. Keep a buffer supply when possible. And never hesitate to reach out to your transplant team if you're struggling to find Myfortic — they're there to help.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
